Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease

International Journal of Pharmaceutics X(2025)10.1016/j.ijpx.2025.100459Source: DataRank Database

Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease is a research paper published in International Journal of Pharmaceutics X (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.00)OA: goldTopics (16)Linked Datasets (10)DataCite Reuse (10)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Devaraj V. Chandrashekar,G. Chuli Roules,Nataraj Jagadeesan ORCID,Emi Iwasaki,Adenike Oyegbesan

Live enrichment

PubMed:41492280 PMC:PMC12765438 OpenAlex:https://openalex.org/W4416901666

National Institute on Aging

Grant: R01AG062840

National Institute on Aging

Grant: R01AG085724

FWCI

0.00

Citation Percentile

0.4%

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ijpx.2025.100459

publisherhttps://doi.org/10.1016/j.ijpx.2025.100459

publisherhttps://api.elsevier.com/content/article/PII:S2590156725001446?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2590156725001446?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41492280

Fields of Study

Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical MethodsMedication Adherence and Compliance

Keywords

ErythropoietinPharmacokineticsMonoclonal antibodyAdverse effectDosingDiseaseIn vivoFusion proteinAntibodyAlzheimer's diseaseBlood-Brain BarrierTransferrin Receptor AntibodyAppsaa Ki Mice

Data set for Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer’s disease.

10.6084/m9.figshare.30977905.v1figshare

Data set for Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer’s disease.

10.6084/m9.figshare.30977905figshare

Iba1 and TREM2 images

10.6084/m9.figshare.30985531.v1figshare

Iba1 and TREM2 images

10.6084/m9.figshare.30985531figshare

6E10 Images

10.6084/m9.figshare.30985594.v1figshare

6E10 Images

10.6084/m9.figshare.30985594figshare